Publications | Venatorx Pharmaceuticals

Publications

News

Venatorx Pharmaceuticals Names William Sargent Senior Vice President, Commercial Strategy

September 17, 2020

Everest Medicines Announces Top-line Results from Phase 1 Clinical Trial of Taniborbactam in Combination with Cefepime in China

September 14, 2020

> See all News

Manuscripts

Click here for Access to the Journal Article

Click here for Access to the Journal Article

>> More Manuscripts

Posters

Rescue of Ceftibuten Activity by the Oral Beta-Lactamase Inhibitor VNRX-7145 against Enterobacteriaceae Expressing Class A, C and/or D Beta-Lactamases.

Evaluation of the in vitro activity of cefepime plus taniborbactam (formerly VNRX-5133) and comparative agents against carbapenem-resistant Enterobacteriaceae.

Oral ceftibuten/VNRX-7145 shows equivalent activity in vitro to IV therapeutics against MDR Enterobacteriaceae.

Cefepime-Taniborbactam (formerly Cefepime/VNRX-5133) Broad-Spectrum Activity is Maintained against Emerging KPC- and PDC-Variants in Multidrug Resistant K. pneumoniae and P. aeruginosa.

>> More Posters